Eisbach Raises $4.5M from Cancer Focus Fund

Eisbach, a Martinsried, Germany-based clinical-stage biotechnology company, received $4.5M from Cancer Focus Fund.

The company intends to use the funds to to support a Phase 1/2 clinical trial of its lead candidate, EIS-12656, which will be conducted at MD Anderson.

Led by Dr. Adrian Schomburg, Founder and CEO, Eisbach is a clinical-stage biotech company focused on precision oncology, aiming to disrupt tumor growth by targeting genetic vulnerabilities. It develops allosteric drugs that selectively disrupt molecular mechanisms, also known as molecular machines, which are vital for tumor genome reorganization.

Eisbach combines the genetic vulnerabilities present in defined tumors (synthetic lethality) with its proprietary drug discovery platform, ALLOS, which targets the molecular vulnerability of its drug targets, to create therapies with fewer side effects.

Commenting on the news, Adrian Schomburg said: “EIS-12656 is a first-in-class small molecule that targets and shuts down the molecular process that reorganizes the tumor genome upon DNA damage and PARP activation – a process that is essential to the survival of cancer cells. Based on its exceptional safety profile and promising activity in preclinical studies, we believe that EIS-12656 has the potential to benefit the many patients with tumors refractory to PARP inhibitors –patients who have few treatment options available today.